My mission to help women be aware of their breast density
I was diagnosed with breast cancer last year after having two clear mammograms. I later underwent a double…
Hospital apologises for diagnosis delay that meant woman had to have mastectomy while pregnant
A hospital has apologised for the failings in care to a mother of two who had to have…
Dense breasts increase risk of missed cancers: ‘My breasts masked a slow-growing tumour’
Dense breasts are relatively normal and common. Around 43% of women who have mammograms in Ireland have dense…
Hyperbaric therapy after breast cancer: managing late radiation side effects
Completing breast cancer treatment is a huge milestone — a moment to celebrate moving forward. But sometimes, months…
Hyperbaric therapy after breast cancer: managing late radiation side effects
Completing breast cancer treatment is a huge milestone — a moment to celebrate moving forward. But sometimes, months…
Lean, mean, breast cancer-fighting machine
Obesity is a modifiable risk factor associated with increased tumour incidence and aggressiveness. Although obesity-associated changes in adipocyte-derived factors…
Finnish study finds poor oral health increases jawbone necrosis risks in breast cancer patients
Antiresorptive drugs, which reduce bone breakdown, are an important part of treatment for breast cancer that has spread…
Cancer survivor Marian urges public to get out and support Pink campaign
A Cork-based breast cancer survivor has made a call to members of the public to support the Irish…
Automated ultrasound offers reliable alternative for screening women with dense breasts
A new study in the Journal of the American College of Radiology, published by Elsevier, has found that…
Metastatic breast cancer: A rapidly changing treatment landscape
As Breast Cancer Awareness Month approaches in October, advances in antibody–drug conjugates, endocrine therapy and molecular profiling are…
Wrap up in ‘PINK’ for Breast Cancer Research
Well-known Irish fashion house Pamela Scott is helping to raise awareness and vital funds for the National Breast…
Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns
HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up…